Atreca Announces Appointment of Kristine M. Ball to its Board of Directors
21 5월 2020 - 9:00PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company
focused on developing novel therapeutics generated through a unique
discovery platform based on interrogation of the active human
immune response, today announced the appointment of Kristine M.
Ball to the company’s Board of Directors. Ms. Ball brings more than
25 years of life sciences industry experience focused primarily on
finance, corporate development and strategic planning.
“We are pleased to announce the appointment of Kristine to our
board of directors,” said John A. Orwin, Chief Executive Officer of
Atreca. “Kristine brings a wealth of expertise gained over her
career in the life sciences industry, during which she established
a track record of executing on effective financing and corporate
development strategies to help build successful companies. She will
be a valuable asset to Atreca as we continue to develop our lead
product candidate, ATRC-101, and begin to advance additional
candidates into the clinic.”
Ms. Ball most recently served as Senior Vice President (SVP) of
Corporate Strategy and Chief Financial Officer (CFO) of Menlo
Therapeutics, Inc., a publicly traded biopharmaceutical company.
Prior to joining Menlo in 2017, Ms. Ball served as SVP and CFO of
Relypsa, Inc., where she helped raise over $675
million in various equity and debt financings and co-led the
cross-functional teams responsible for closing partnerships with
Sanofi and Vifor Fresenius Medical Care Renal Pharma, as well as
the company's acquisition by Galenica. Prior to Relypsa, Ms. Ball
previously served as SVP, Finance and Administration and CFO of KAI
Pharmaceuticals, Inc. (acquired by Amgen) and Vice President,
Finance at Exelixis, Inc. Before joining Exelixis, Ms. Ball was a
senior manager in Ernst & Young's life sciences audit
practice. Ms. Ball holds a B.S. from Babson College. She
also served on the Board of Directors of Forty Seven Inc. prior to
the company’s recent acquisition by Gilead.
“Atreca’s differentiated discovery platform has shown the
ability to generate novel and potentially efficacious therapeutics
for the treatment of large groups of patients in oncology,” said
Ms. Ball. “I am excited to join the team during an important phase
for a growing company and I very much look forward to being a part
of Atreca’s continued progress and success.”
About Atreca, Inc. Atreca is a
biopharmaceutical company developing novel antibody-based
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumors. These antibodies provide
the basis for first-in-class therapeutic candidates, such as our
lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please
visit www.atreca.com.
Forward-Looking Statements
This release contains forward-looking statements regarding our
strategy and future plans, including statements regarding the
development of ATRC-101 and our clinical and regulatory plans, and
the timing thereof. These forward-looking statements include, but
are not limited to, statements about our plans, objectives,
representations and contentions and are not historical facts and
typically are identified by use of terms such as “will,”
“potential,” “continue,” “begin,” and similar words, although some
forward-looking statements are expressed differently. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, any clinical trials and
Investigational New Drug application and other regulatory
submissions, and other matters that are described in our most
recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission (SEC)
and available on the SEC’s website at www.sec.gov, including
the risk factors set forth therein. Investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this release, and we undertake no
obligation to update any forward-looking statement in this press
release, except as required by law.
Contacts
Atreca, Inc. Herb Cross Chief Financial Officer info@atreca.com
Investors: Alex Gray, 650-779-9251 agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024